CurrentPremera BluecrossPolicy N/A

Pulsed Radiofrequency for the Treatment of Chronic Pain

This policy governs coverage of pulsed radiofrequency (PRF) procedures for treating various chronic pain syndromes for Premera Blue Cross members and informs providers when PRF is considered investigational versus supported by evidence.

Policy Summary

PayerPremera Bluecross

PolicyPulsed Radiofrequency for the Treatment of Chronic Pain

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateSep 12, 2025

Next Review DateSep 12, 2025

Key ActionVerify member benefits and any prior authorization requirements with the insurer before performing pulsed radiofrequency procedures.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

manyindications investigational

1unlisted CPT referenced

multipleFDA-cleared generators

ongoingclinical trials

investigationalpolicy stance

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Investigational / Not Medically Necessary

Pulsed radiofrequency is classified as investigational for treatment of the following chronic syndromes (including but not limited to):

Investigational indications list: Pulsed radiofrequency (PRF) is investigational for a broad range of chronic pain conditions including, but not limited to: anterior cutaneous nerve entrapment syndrome (abdominal pain); auriculotemporal neuralgia; carpal tunnel syndrome; chronic facial and head pain (persistent idiopathic facial pain/PIFP and sphenopalatine ganglion); coccydynia; complex regional pain syndrome (reflex sympathetic dystrophy); diabetic peripheral neuropathy; discogenic pain; facet (zygapophyseal) joint pain (cervical, lumbar, thoracic, sacro-iliac); frozen shoulder (adhesive capsulitis); genitofemoral neuralgia (scrotal or post-herniorrhaphy pain); headaches (cervicogenic, migraine, cluster, tension); inguinal neuralgia; intercostal neuralgia (post-surgical thoracic pain); low back pain; lumbosacral radicular pain (dorsal root ganglion); meralgia paresthetica; metacarpal or metatarsal joint pain; Morton's neuroma; myofascial syndrome; neck (cervical radicular pain); occipital neuralgia; ophthalmic neuralgia; orchialgia; osteoarthritis of the knee (genicular or saphenous nerve) or hip pain; pelvic pain (e.g., superior hypogastric plexus for interstitial cystitis); peripheral neuromas; piriformis syndrome; plantar fasciitis (medial calcaneal nerve); post-herpetic neuralgia; postoperative abdominal wall pain (incisional pain outside anterior cutaneous nerve entrapment); pudendal neuralgia; sacro-iliac joint pain; shoulder pain (suprascapular nerve, including hemiplegic shoulder pain after stroke); tarsal tunnel syndrome; trigeminal neuralgia (Gasserian ganglion); vulvodynia; and other chronic pain syndromes enumerated in the policy.

Investigational / Not medically necessary

Policy position from history entries:

Investigational designation: Pulsed radiofrequency for the treatment of various chronic pain syndromes is considered investigational.

History documents repeated annual reviews and additions to the list of chronic syndromes designated investigational (see history entries noting additions such as anterior cutaneous nerve entrapment syndrome, auriculotemporal neuralgia, genitofemoral neuralgia, and postoperative abdominal wall pain).

Pulsed radiofrequency (PRF) is designated investigational for the treatment of a broad set of chronic pain syndromes. The policy explicitly lists, but is not limited to, the following conditions: anterior cutaneous nerve entrapment syndrome (abdominal pain), auriculotemporal neuralgia, carpal tunnel syndrome, chronic facial and head pain (persistent idiopathic facial pain/sphenopalatine ganglion), coccydynia, complex regional pain syndrome, diabetic peripheral neuropathy, discogenic pain, facet joint pain (cervical, lumbar, thoracic, sacro-iliac), frozen shoulder (adhesive capsulitis), genitofemoral neuralgia, cervicogenic and other headaches (migraine, cluster, tension), inguinal neuralgia, intercostal neuralgia, low back pain, lumbosacral radicular (dorsal root ganglion) pain, meralgia paresthetica, metacarpal/metatarsal joint pain, Morton's neuroma, myofascial syndrome, neck (cervical radicular) pain, occipital neuralgia, ophthalmic neuralgia, orchialgia, osteoarthritis knee/hip pain, peripheral neuromas, piriformis syndrome, plantar fasciitis, post-herpetic neuralgia, postoperative abdominal wall pain, pudendal neuralgia, sacro-iliac joint pain, shoulder pain (suprascapular nerve), tarsal tunnel syndrome, trigeminal neuralgia, and vulvodynia.

The policy history documents that PRF was established as investigational at policy inception and that the investigational listing has been maintained through subsequent annual reviews. Additions to the investigational list over time include anterior cutaneous nerve entrapment syndrome (added 10/01/24) and, most recently (09/01/25), auriculotemporal neuralgia, genitofemoral neuralgia (scrotal or post-herniorrhaphy), and postoperative abdominal wall pain (incisional pain outside anterior cutaneous nerve entrapment).

The policy concludes PRF is investigational because available evidence is limited and does not demonstrate consistent, robust benefit across the many chronic syndromes listed. Literature reviews performed at policy inception and during multiple annual updates found insufficient controlled data and lacking comparative-effectiveness evidence versus conventional treatments to establish PRF as medically necessary for these indications.

Accordingly, pulsed radiofrequency is designated investigational and not covered for the chronic pain syndromes listed in this policy. Claims submitted for PRF to treat those indications are subject to denial as investigational per the policy position.

Coding and Billing Codes

Referenced CPT CodesCPT

64999

Unlisted procedure; nervous system

Provider Actions and Billing Guidance

Prior Authorization

Verify benefits / Prior authorization

Prior authorization and benefit verification requirements vary by contract. Providers must verify member benefits and obtain prior authorization when required by the member's plan before scheduling pulsed radiofrequency procedures.

Verify benefits and prior authorization with Premera prior to the procedure.
Member contracts differ; coverage is subject to plan limits and conditions.

Note

Evidence and comparative data

Pulsed radiofrequency is designated investigational due to limited controlled clinical data, inconsistent findings across small trials, and a lack of comparative effectiveness data versus conventional treatments. The available evidence includes a small number of randomized trials, nonrandomized studies, and case reports with methodological limitations and short follow-up.

Evidence insufficient to determine impact on health outcomes; further well-designed RCTs with larger sample sizes and long-term follow-up are needed.
Comparative data versus conventional treatments are lacking; investigational designation may lead to noncoverage.

Billing Rule

Billing code documentation

Use CPT 64999 (unlisted procedure, nervous system) for billing pulsed radiofrequency procedures when no specific CPT code exists. When using an unlisted code, submit operative reports and supporting documentation that fully describe the procedure, indication, technique, and duration to allow claims adjudication.

Report CPT 64999 with a detailed operative/procedure note attached.
Include documentation of diagnosis, target nerve/structure, pulses delivered, energy settings, and clinical rationale.
Claims for investigational indications may be denied if documentation does not support medical necessity or if the service is considered investigational under the member's plan.

Denial Risk

Investigational designation and denial risk

Claims for services characterized as investigational are subject to denial under applicable benefit plans. Providers should be prepared to supply complete clinical documentation to support medical necessity if requesting coverage for these procedures.

Investigational designation may lead to noncoverage/denial.
Consult the member benefit booklet or Premera customer service for benefit-specific determinations.

Documentation Required

Provider action — benefit verification

Provider action: contact member services or refer to the member benefit booklet for final coverage determination and any required precertification steps.

Confirm whether the member's plan excludes investigational services such as pulsed radiofrequency.
Obtain any required precertification or prior authorization prior to performing the procedure.

Definitions

Pulsed radiofrequency (PRF) definition — non/neurodestructive technique summary

DefinitionPulsed radiofrequency (PRF) is a non- or minimally neurodestructive technique that delivers short bursts of radiofrequency energy to nervous tissue to modulate nerve activity while keeping temperatures below neurodestructive levels.

Mechanism detailEnergy is applied in short intermittent bursts (allowing cooling between pulses) so average temperatures do not reach levels that would ablate nerve tissue.

Output characteristicPulsed PRF output has been described at about 45 volts allowing higher electrical fields than continuous RF while avoiding neurodestructive temperatures.

Intended effectAims for neuromodulation rather than neuroablation, theorized to reduce complications associated with continuous RF.

Pulsed radiofrequency — short reference to PRF procedures

Typical proceduresPRF has been applied to peripheral nerves, dorsal root ganglia, and named ganglia (examples include suprascapular, saphenous, pudendal, genicular nerves and the Gasserian/sphenopalatine ganglia).

Delivery patternDelivered as short bursts (e.g., twice per second) with quiet phases between pulses to permit electrode cooling.

Clinical use casesUsed for peripheral neuropathies, arthrogenic pain, trigger points, radiculopathy, and other chronic pain syndromes.

Conservative Treatment Requirements

Benefit consultation note

Benefit verification and plan consultation guidance:

Benefit consultation: Providers and members should consult the member benefit booklet or contact a member service representative to determine whether there are any benefit limitations or prior authorization requirements applicable to pulsed radiofrequency procedures.

Conservative therapy prerequisites or specific conservative treatment durations are not specified in this excerpt of the policy.

Frequency Limits

Frequency limits — inventory item present but no content in excerpt

Frequency limits (policy)No frequency limits specified in the policy excerpt.

Procedure-specific limitsNot provided in this document excerpt; refer to member benefits or prior authorization guidelines if applicable.

Recommendation to providersVerify benefit coverage and any applicable limits with the insurer prior to scheduling repeat PRF procedures.

Frequency limits — not specified in this excerpt

Stated availability in excerptFrequency limits are not specified in this excerpt of the policy.

Action itemProviders and members should consult the member benefit booklet or contact customer service to determine any applicable frequency limitations.

Fallback guidanceFollow standard clinical practice and device labeling for repeat procedures when policy is silent.

Imaging Requirements

Note

Imaging guidance: follow standard practice and device labeling

Follow standard clinical practice and device labeling for any imaging guidance, because the policy excerpt does not specify imaging requirements for PRF procedures.

Use fluoroscopy, ultrasound, or other imaging as indicated by the procedure, local practice, and device instructions for use.

Documentation Required

Policy does not specify imaging — use standard imaging practices

No specific imaging requirements are specified in the policy excerpt; providers should use appropriate imaging based on standard of care and device instructions.

Document the imaging modality used and the rationale when submitting prior authorization or claims, if applicable.

Background

Pulsed radiofrequency delivers short bursts of radiofrequency energy to nervous tissue at parameters intended to keep tissue temperatures below neurodestructive levels, producing neuromodulation rather than thermal ablation. The technique was introduced as a less destructive alternative to continuous radiofrequency and is used across peripheral nerves, dorsal root ganglia, and named ganglia (examples cited in the policy references), but randomized and comparative data remain limited.

Not Covered

Not covered: all specific chronic pain indications enumerated as investigational in this policy. Examples include anterior cutaneous nerve entrapment syndrome; auriculotemporal neuralgia; genitofemoral neuralgia (scrotal or post-herniorrhaphy); postoperative abdominal wall pain (incisional pain outside anterior cutaneous nerve entrapment); peripheral neuromas; pudendal neuralgia; trigeminal, occipital, and ophthalmic neuralgias; lumbosacral radicular (dorsal root ganglion) pain; genicular nerve PRF for osteoarthritis; and others listed above. Procedures for these indications are subject to noncoverage/denial as investigational per the policy.